Firma Vai Hong
Concise Prescribing Info
As standard therapy for induction of clinical remission &/or as maintenance therapy in patients w/ acute non-lymphoblastic leukaemia, acute lymphoblastic leukemia, acute myeloid leukemia, diffuse histiocytic lymphoma (non-Hodgkin's lymphoma of high malignancy). As high-dose therapy in patients w/ refractory acute non-lymphoblastic leukaemia, refractory acute lymphoblastic leukaemia, blast crisis of chronic myeloid leukaemia, leukaemias that confer a particular risk (eg, acute leukemias as a secondary malignancy following previous chemotherapy &/or radiotherapy), refractory non-Hodgkin's lymphoma.
Dosage/Direction for Use
Induction therapy of acute leukaemias IV inj 100-200 mg/m2/day or IV infusion 100 mg/m2/day. Maintenance therapy of leukaemia 75-100 mg/m2/day once a mth on 5 consecutive days or once a wk. CNS involvement 10-30 mg/m2/day 3 times a wk intrathecally. Lymphoma Treat w/ appropriate combination therapy. High-Dose therapy: 2-3 g/m2 12 hrly for 4-12 doses.
Hypersensitivity. Patients w/ pre-existing bone marrow suppression. Severe hepatic &/or renal impairment, pre-existing severe infections, peptic ulcer & recent surgery. Leukopenia &/or thrombocytopenia of non-malignant aetiology. Pregnancy & lactation.
Special Precautions
Monitor white cell & platelet counts regularly even once treatment has ended. Prophylaxis of hyperuricaemia is advisable in patients w/ high blast counts or extensive tumour masses. Mild hepatic & renal impairment. Patients should drink plenty of fluids. May have mutagenic effect. Severe GI side effects necessitate antiemetic & other supportive measures. Regular monitoring of hepatic & renal function, uric acid, CNS & lung function. Irrigate eyes regularly during high-dose therapy. Avoid immunisation w/ live vaccines. Risk of haemorrhagic complications & severe infections. Avoid contact w/ skin & mucous membranes. May transiently impair responsiveness of patient. Elderly >60 yr during high-dose therapy.
Adverse Reactions
Bone marrow depression. Conventional dose: Leukopenia; nausea, vomiting, diarrhoea; maculopapular rash, ulceration, erythroderma or erythema, mottled skin, pruritus; pulmonary oedema. High dose: Myelotoxicity; mucositis & mucosal ulceration; generalised erythema; cerebral/cerebellar disorders, headache, dizziness, disturbances of thought processes & movements, somnolence, lethargy, coma, convulsions & anorexia; myalgia &/or arthralgia; conjunctivitis, keratitis, photophobia, sore eyes, severe lacrimation & visual disturbances; impaired liver function; elevated plasma creatinine.
Drug Interactions
Acute pancreatitis w/ previous treatment of L-asparaginase. Myelotoxic interaction w/ other drugs that have toxic effect on bone marrow. Inhibited antifungal action of flucytosine.
ATC Classification
L01BC01 - cytarabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Alexan inj 50 mg/mL
10 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in